Member Info for Porter_

Any new market makers entered the game?

Boom!

Great news and well done Eric for putting your money where your mouth is too. So happy that the allocation went to existing investors, as we have a good bunch who care about the future of the company long term, and even better to know it was done at such a premium to the original offer!

Should get that 4m grant any day soon and Genflow should fly to the moon!

Genflow Biosciences is a UK-based biotechnology company developing gene therapies to target the aging process and age-related diseases, using a variant of the SIRT6 gene found in centenarians delivered via adenoviral vectors. Their lead candidate, GF-1002, aims to slow or halt aging by increasing SIRT6 levels, with other programs including treatments for muscle aging (sarcopenia), glaucoma, and a veterinary anti-aging therapy for dogs (GF-1004). The company has research facilities in Belgium and is conducting a human proof-of-concept trial for Werner Syndrome, a model for premature aging.

Key Aspects of Genflow Biosciences:

Focus: Longevity, aiming to extend healthspan and reduce age-related diseases through gene therapy.

Technology: Utilizes adeno-associated virus (AAV) vectors to deliver a centenarian variant of the human SIRT6 gene into cells.

SIRT6 Gene: Believed to be a master regulator of healthy aging, as increased levels are linked to prolonged lifespan and improved DNA repair in mice.

Pipeline:

GF-1002: The lead intravenous gene therapy candidate for human anti-aging.

GF-1003: A topical formulation of the SIRT6 gene therapy for skin aging.

GF-1004: A non-human version of GF-1002 for veterinary (dog) use.

GF-1005: A therapy for sarcopenia (muscle loss) by targeting mitochondrial dysfunction.

GF-1006: An mRNA therapy for corneal pathologies and glaucoma.

Research & Clinical Trials: Conducting a Phase I/II trial for Werner Syndrome, a model for premature aging, to gain insights into the aging process.

Location: Headquartered in London, with R&D facilities in Belgium and a U.S. office in Cambridge, MA.

Key Aspects:

2 x NDA’s signed for potential deal/s on the pet programme

2 patents in final European Patent Office review with positive indications on both

Similar companies sell their early stage programmes in the $bn’s

Further grant funding expected

Directors are some of the most respectable in the Pharma longevity and MRNA field, who have patents in their own right and $bn’s in deals under their belt

The 5 programmes have multiple SIRT compounds and patient type uses, so could be used for multiple therapies if procured by the right Pharma

All programmes currently advancing, which could result in early stage takeover on a programme or the company as a whole

€6m MCAP NE, last I’d added up, Genflow had been given about €14m to develop the portfolio, so hard to believe it has such a low valuation:

- 26th March 2025 - £484,000 investment towards new dog trial programme

- 22nd October 2024 - €4m non dilutive grant / loan (Wallonia Region)

- 30th May 2024 - €800,000 non dilutive grant (Government of Wallonia in Belgium's Advanced Therapy Medicinal Products)

- 4th April 2024 - £715,000 Capital Plus Partners placing, new TR1 private investor and new institutional investors

- 18th January 2024 - €1.34m non dilutive grant

- 18th January 2024 - €1.55m non dilutive grant

- 11th October 2022 - €250,000 non dilutive grant (Applied Research Programme of Enterprise Estonia)

- 16th March 2022 - €3.375m non dilutive grant (Regional Government of Wallonia)

Agree NE -

Possible upcoming news:

4.7m grant

Patents being granted and licensing fees start coming in

Dog deals secured with the 2 pet pharma companies under NDA and maybe even more!

Potential programme or total company takeovers

New programmes being announced

New JV’s

Further grants

Further patents being submitted

Research publications

Growth of management team

Anything could happen!

Sept - Shares in Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) climbed after the London-listed biotech announced talks with two major animal health companies to explore the use of its longevity research in pets.

The company, which is the only quoted group in Europe focused on ageing, said the confidentiality agreements will allow it to exchange data and begin talks over potential collaborations.

Genflow is developing a gene therapy based on a variant of the SIRT6 gene, associated with people who live beyond 100 years.

It is already testing the treatment in beagles through its GF-1004 dog ageing study, where no safety issues have been reported to date.

The new partnerships aim to assess whether the same approach could extend the healthy lifespan of dogs and other companion animals, a sector that has grown rapidly as owners spend more on advanced treatments.

Eric Leire, chief executive, said the deals reflect “strong industry interest” and could pave the way for licensing agreements and eventual commercialisation.

Genflow added that partnering with a larger pharmaceutical group would accelerate market access by providing regulatory expertise and established distribution networks.

As long as they’re looking out for your wellbeing and not keeping them for their mates Rooster, that’s the main thing.

Have you called and asked them why the change? Would love to know why they’re targeting Genflow?

Is that just Genf rooster? Sounds like you need to get a proper broker!

So much good news in the pipeline Money. Wouldn’t surprise me if we get back up to 5p before Xmas so the shares are at a bargain rate right now.

Bit strange that we can’t see all the trades that have gone through. Is LSE broken this morning?

I’ve been asking around and told some brokers do tend to forward sell and they’re saying it’s not illegal, but that they then have to find the shares with-in 20 days. Squeaky bum if they then can’t get the shares or they rocket, to which they’d have to buy on the open market, which as we know, Genflow have hit 12p before, so that’s a massive loss to the institution if they have to cover the difference from 0.85p. I just don’t think there are enough shares in circulation to cover a gap like that, so there would imminently be a squeeze. The only logical explanation is that the broker who was expecting to win the allotment forward sold, but as noted, the shares have been formally awarded yet, so it seems very risky on their part.

In an industry where companies are acquired for $bn’s, Genflow Biosciences has several programs targeting age-related conditions:

MASH (liver disease) and Werner Syndrome (premature aging), with clinical trials underway or planned. They are also developing programs for sarcopenia (muscle loss) and ophthalmology (eye diseases), along with a veterinary life extension trial for dogs. The company's approach focuses on its proprietary Centenarian SIRT6 (cSIRT6) technology and partnerships.

Human Health Programs

MASH (Metabolic Dysfunction-Associated Steatohepatitis):

Genflow is advancing a candidate, GF-1002, for this liver disease, with a Phase I/II trial planned and positive preclinical data showing anti-fibrotic and anti-tumoral effects.

Werner Syndrome:

The company is initiating a Phase I/II trial for Werner Syndrome, a genetic disorder that causes premature aging, to gain insights into the aging process.

Sarcopenia:

Genflow is developing therapies to address mitochondrial dysfunction in sarcopenia, a condition characterized by muscle loss, through a collaboration with Université libre de Bruxelles.

Ophthalmology:

A new program has been launched using the cSIRT6 technology and a non-viral vector for eye disease treatment.

Animal Health Programs

Dog Aging Program (GF-1004):

Genflow has begun a six-month life extension clinical trial in aging dogs to assess the health span and lifespan potential of their gene therapy.

Enabling Technologies

Centenarian SIRT6 (cSIRT6) Technology:

This platform is central to their therapeutic development across human and animal health.

Partnerships and Collaboration:

Genflow works with research institutions and partners like Syngene for the dog aging study and Université libre de Bruxelles for sarcopenia research.

Artificial Intelligence (AI):

An AI-powered partnership helps identify patients most likely to respond to the therapies.

Rooster, I can’t imagine it’s the placing shares, as I haven’t seen confirmation they’ve been admitted into the register or with companies house as of yet… unless they’ve been forward sold at institutional risk 🤷🏼

Don’t worry, we’ll get a good German comedian for your role 😆

Sounds like a ransome more than a raising of funds. Hold tight before reacting, more news expected...

Start picking who will play your character in Genflow the movie, being released in 2030 😁

Imagine the shockwaves across the stock market if a shareholders uprising does actually result in a market maker pushing a duress placing getting kicked TF.

There are a number of HNW’s in Genflow with hefty positions not to be F’d with.

Looks like the sells sucked up by discount buyers money. Xmas come early .

Genflow Biosciences is working on gene therapies to slow the aging process, with key programs including: GF-1002 for MASH (a chronic liver disease) and Werner Syndrome, GF-1003 for Werner Syndrome, and GF-1004 in a clinical trial for dog aging. The company's lead approach involves the SIRT6 gene, using a "centenarian" variant found in long-lived individuals.

Here's a breakdown of their main programs:

MASH (Metabolic Dysfunction-Associated Steatohepatitis) - GF-1002:

Genflow is developing GF-1002, a SIRT6-based gene therapy to treat MASH, a prevalent chronic liver disease. The program has advanced to the pre-IND phase of preclinical development and is moving toward human clinical trials.

Werner Syndrome - GF-1003:

They are also working on GF-1003 to address Werner Syndrome, a progeria-related genetic disorder that causes premature aging. This involves creating a unique liver organoid model to better predict the drug's effects in humans.

Dog Aging - GF-1004:

Genflow has a clinical trial for aging dogs to assess the therapeutic effects of a veterinary version of their gene therapy on both lifespan and healthspan.

Sarcopenia - GF-1005:

Genflow is also researching sarcopenia, the age-related loss of muscle mass. This work involves loading muscle progenitor cells with the SIRT6 gene to restore mitochondrial health and combat muscle loss.

Eye Diseases:

Genflow is exploring the use of SIRT6 to treat eye conditions like glaucoma and corneal endothelial disorders.